Computer Aided Multispectral Ulstrasound Diagnostic Device

Projektinformationen

UltraEASY

ID Finanzhilfevereinbarung: 683405

DOI

10.3030/683405

Projekt abgeschlossen

EK-Unterschriftsdatum 6 Juni 2015

Startdatum 1 Juli 2015

Enddatum 31 Oktober 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

SONOVUM AG
Germany

Periodic Reporting for period 1 - UltraEASY (Computer Aided Multispectral Ulstrasound Diagnostic Device)

Berichtszeitraum: 2015-07-01 bis 2015-10-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

"The action context of the feasibility study is the clinical validation of SoNovum AG’s UltraEASY™ II Brain Vitals Monitoring and Diagnostic System for examination of neuropathologies in acute events and at-risk patient groups as well as for preventive patient screening. The brain monitoring system uses the novel diagnostic method acousto-cerebro-graphy (ACG), supported by ""CAMUD"" Computer Aid Multispectral Ultrasound Diagnosis.

The objectives of this project are the examination of the market acceptance of UltraEASY II System (in its todays appirience), the risk evaluation for the final realization of the ACG technology in the MedTech sector and, lastly, the development of final innovation strategies for Phase 2. With the results, the overall strategy of the development project will be adjusted. The current 2015 Business Plan will be validated and optimized in both aspects, System Design and usability as well as marketing strategy accordingly."

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

In detail, the study of market acceptance has clarified the need for new/alternative diagnostic methods (preventive and acute diagnostics), the technical/economic requirements, the acceptance of diagnostic methods without specialized physicians to cover follow-up costs and the willingness to cover the costs (full/partial) of preventive diagnostics for risk patients. The examination was conducted in Spain, Italy, France, UK, Poland and Germany, addressing clinics (with and without stroke units) and physicians as well as involving patients, patient organizations and health insurance carriers.

It was followed by the risk evaluation of final realization of the ACG technology in the MedTech sector and the development of final innovation strategies for further development in Phase 2.

The main result achieved so far is a study, validating a high demand and high acceptance of the ACG technology introduction for physicians, ambulances, rescue helicopters and rehabilitation facilities. There is also a demand and acceptance in clinics, where it can be used adjuvant to the current MRI/CT gold standard.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

The final result of the project will be the market readiness of the UltraEASY II diagnostic device. Though applicable in the diagnosis of neuropathologies in general, the main application field of UltraEASY will be preventive screening of the patient with emphasising risk group patient e.g. AF Patient the and quick diagnoses of strokes, when CT/MRI devices take too much time or are not within reach. Every 40 seconds, someone in Europe suffers from a stroke. The resulting economic damage in Europe amounts to 36 billion EUR per year. In addition to that the direct and indirect costs of medical therapy are estimated to be 10 billion EUR per year. In total the EU predicts 108 billion EUR costs over the next 20 years for stroke therapy.

Groups of players

Effectiveness of current methods in early stroke diagnosis

Need of new methods in early stroke diagnosis